Company news

BridgeBio Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors

June 23, 2020

BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases

June 17, 2020

BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

June 10, 2020

BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update

May 12, 2020

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia

May 10, 2020

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

March 11, 2020

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

March 3, 2020

BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

March 1, 2020

BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors

February 23, 2020

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

January 12, 2020

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

January 9, 2020

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

January 5, 2020

BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

December 17, 2019

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

December 15, 2019

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

December 8, 2019

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

December 2, 2019

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

November 6, 2019

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

October 21, 2019

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

October 13, 2019

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.